- Home
- PAYO vs KNSA Comparison
PAYO vs KNSA Comparison
Compare PAYO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- KNSA
- Stock Information
- Founded
- PAYO 2005
- KNSA 2015
- Country
- PAYO United States
- KNSA United Kingdom
- Employees
- PAYO N/A
- KNSA N/A
- Industry
- PAYO EDP Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- KNSA Health Care
- Exchange
- PAYO Nasdaq
- KNSA Nasdaq
- Market Cap
- PAYO 2.2B
- KNSA 1.9B
- IPO Year
- PAYO N/A
- KNSA 2018
- Fundamental
- Price
- PAYO $6.81
- KNSA $27.36
- Analyst Decision
- PAYO Strong Buy
- KNSA Strong Buy
- Analyst Count
- PAYO 8
- KNSA 5
- Target Price
- PAYO $10.44
- KNSA $38.80
- AVG Volume (30 Days)
- PAYO 4.4M
- KNSA 474.9K
- Earning Date
- PAYO 05-07-2025
- KNSA 07-22-2025
- Dividend Yield
- PAYO N/A
- KNSA N/A
- EPS Growth
- PAYO N/A
- KNSA N/A
- EPS
- PAYO 0.28
- KNSA N/A
- Revenue
- PAYO $996,150,000.00
- KNSA $481,166,000.00
- Revenue This Year
- PAYO $4.12
- KNSA $37.21
- Revenue Next Year
- PAYO $4.91
- KNSA $5.32
- P/E Ratio
- PAYO $24.29
- KNSA N/A
- Revenue Growth
- PAYO 14.86
- KNSA 59.45
- 52 Week Low
- PAYO $5.03
- KNSA $17.38
- 52 Week High
- PAYO $11.29
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- PAYO 46.54
- KNSA 62.48
- Support Level
- PAYO $6.77
- KNSA $26.28
- Resistance Level
- PAYO $6.94
- KNSA $27.90
- Average True Range (ATR)
- PAYO 0.21
- KNSA 0.99
- MACD
- PAYO -0.02
- KNSA -0.07
- Stochastic Oscillator
- PAYO 12.30
- KNSA 82.30
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.